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W
ith a forceful gesture, the 
delicate blond unlocks the 
heavy door of a cell in Riga’s 
Central Prison clinic (Figure 1). Her 
name is Dr. Inga Nagele. She is the 
head of the clinic’s tuberculosis (TB) 
unit. She opens the door to check on 
three female prisoners who have just 
been admitted. The conditions in the 
cell are bleak. Washing hangs on a 
line that stretches from one wall to the 
other. The bars on the small window 
hardly let any light into the room, and 
a bucket in the corner serves as a toilet. 
All the women were infected with TB at 
the prison. 
“Living conditions in Latvia’s prisons 
are miserable. This is ideal for a 
relentless spread of the life-threatening 
lung bacteria and other communicable 
diseases”, says Dr. Nagele. Because 
of permanent overcrowding, poor 
hygiene, and frequent relocation of 
prisoners within Latvia’s 15 prisons, 
two-thirds of inmates infected with TB 
developed the disease once they were 
locked up, she says. 
Latvia has 352 prisoners per 100 
000 individuals in the population 
[1]. This number makes it one of the 
countries with the highest proportion 
of prisoners in the European Union, 
according to Mihails Azarenko, 
Chief of Riga’s Central Prison. It is 
particularly high when compared with 
Denmark, for example, which has only 
64 prisoners per 100 000 individuals 
[1].
Rising TB Rate after the Breakdown 
of the Soviet System
Outside Latvia’s prisons, the 
conditions were just as favourable for 
an unchecked spread of infectious 
diseases, and TB in particular. The 
fall of the Soviet Union in 1991, and 
with it the collapse of a centralised 
public-health system, left the 
population in the newly independent 
states without proper access to 
health care. Latvia struggled against 
soaring unemployment, poverty, and 
alcoholism. These transition problems 
led to a rapid increase of TB and the 
development of multidrug-resistant TB 
(MDR-TB) strains. 
MDR-TB is a form of the disease 
resistant to at least two of the most 
powerful conventional antibiotics 
that can treat TB (rifampicin and 
isoniazid). It develops when public-
health programs fail to deliver regular, 
reliable treatment to patients. While 
the common strain of TB can be cured 
at a cost of US$10 for a six-month 
treatment course, MDR-TB can cost 
100 times as much and takes two years 
to treat. 
According to the World Health 
Organization’s (WHO’s) “Global 
Health in Action
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Tuberculosis Control” report [2], 
reported notiﬁ  cations of TB in 
Latvia peaked in 1998 with 90 cases 
per 100 000 individuals. This made 
Latvia the country with the highest 
TB incidence rate in the European 
Union, compared with an average rate 
of 13 per 100 000 in western Europe. 
It was also considerably higher than 
in the other two Baltic states, Estonia 
(48 per 100 000) and Lithuania (70 
per 100 000). Rates of MDR-TB in 
Latvia are among the highest in the 
world. According to a report by the 
WHO and the International Union 
Against Tuberculosis and Lung Disease, 
patients in parts of eastern Europe and 
central Asia are ten times more likely 
to have MDR-TB than in the rest of the 
world [3]. 
Rinalds Mucins, former Health 
Minister of Latvia, sees the main reason 
for Latvia’s health problems as the 
difﬁ  cult transition process of the health 
system. He was part of a government 
that resigned on 28 October 2004, 
when parliament rejected the prime 
minister’s draft budget. “Over the past 
ten years we have tried every health 
system from Semashko to Bismarck. 
We changed our system too many times 
and too rapidly and couldn’t provide 
patients and doctors with any stability”, 
he says. “Now we are working on some 
long-term programs; this is deﬁ  nitely a 
good start.”
Implementing DOTS 
and DOTS-Plus
This good start has already yielded 
positive results. Since 1995, Latvia has 
begun to make great strides in reducing 
the threat of TB and has started to 
rigorously implement DOTS, the 
internationally recommended strategy 
for controlling TB (see Sidebar). 
The government backed this up 
with a strong political and ﬁ  nancial 
commitment, resulting in TB cure 
rates rising from 64% in 1997 to 
73% in 2002, according to the WHO 
European Regional Ofﬁ  ce centralised 
information system for infectious 
diseases. As a response to the serious 
MDR-TB situation, the DOTS-Plus 
project was introduced a couple of 
years later in close collaboration 
with the WHO and the United States 
Centers for Disease Control and 
Prevention. The DOTS-Plus project 
was also approved by the Green Light 
Committee. This committee is the 
technical review panel of the Green 
Light Committee mechanism, the 
WHO’s mechanism to enable access to 
quality-assured second-line drugs at a 
reduced cost and technical assistance in 
the management of MDR-TB [4].  
DOTS-Plus targets MDR-TB and 
builds on the elements of the DOTS 
strategy. However, it also takes into 
account speciﬁ  c issues, such as the use 
of second-line drugs, that need to be 
addressed in areas with a signiﬁ  cant 
prevalence of MDR-TB. “DOTS-Plus has 
been very effective so far. According to 
the State Centre of Tuberculosis and 
Lung Diseases the number of MDR-
TB cases decreased by 50%, from 335 
cases in 1997 to 166 in 2003”, says Dr. 
Aiga Rurane, head of the WHO Liaison 
Ofﬁ  ce in Riga, “However, much more 
remains to be done to fully control the 
spread of MDR-TB.” 
In 1997, TB control in prisons 
became part of Latvia’s National 
TB Control Program. Since then, 
all prisoners undergo regular 
examinations and sputum tests. With 
an 85.9% cure rate, the number of 
patients with TB who are cured in 
prisons is now higher than outside. 
According to ofﬁ  cial data provided 
by the State Centre of Tuberculosis 
and Lung Diseases (http:⁄⁄www.
tuberculosis.lv), the number of cases 
of MDR-TB in prisons was reduced 
from 19 in 2000 to nine in 2003 [5]. 
“The reason for these good cure rates 
is that patients are under permanent 
surveillance and must swallow the 
prescribed drugs,” says Dr. Nagele. “It 
also helps that they get a warm meal 
and regular sleeping hours.”
Dr. Gunta Dravniece, head of the 
MDR-TB ward in Riga’s State Agency 
for TB and Lung Diseases, believes that 
controlling TB inside prisons is key to 
preventing the spread of the disease 
in the rest of the country. The State 
Agency for TB and Lung Diseases is 
located in a forest, a half-hour drive 
outside Riga. It was built in the 1950s 
by prisoners and designed as an 
isolation hospital for Riga’s patients 
with TB. It has separate sections for 
patients with TB and MDR-TB.
At least one-third of Dr. Dravniece’s 
patients in the MDR-TB ward are ex-
prisoners. The others are often socially 
disadvantaged, homeless, and suffering 
from chronic alcoholism. “Many of them 
don’t have even a passport,” she says. 
“When they get infected with MDR-TB, 
they want to stay as long as possible here 
at the state agency clinic, because they 
have a bed and something to eat.” 
Long-term treatment, which is a 
necessity for MDR-TB, is difﬁ  cult for 
both patients and health workers. 
Patients have to take up to 25 pills every 
day. Nurse Valentina carefully watches 
that each of the 55 patients with MDR-
TB in the ward takes them. “They don’t 
like these drugs, because often the 
pills provoke sickness and are difﬁ  cult 
to digest. So I have to explain to them 
over and over why it is so important 
to take the medication regularly”, she 
explains. 
Once patients are not infectious 
anymore, they can leave the ward and 
go back to their hometowns. There 
they receive almost daily follow-up 
treatment by local doctors and nurses. 
“Patients who come for their medical 
checks get food and are reimbursed for 
transportation. This is cheaper for the 
public sector than the hospital cost and 
motivates them to come back”, says Dr. 
Dravniece. 
DOTS and DOTS-Plus
DOTS (for “directly observed treatment, 
short course”) is the internationally 
recommended TB control strategy that 
combines ﬁ  ve elements: sustained 
political commitment; access to 
quality-assured TB sputum microscopy; 
standardized short-course chemotherapy 
to all cases of TB under proper case-
management conditions; uninterrupted 
supply of quality-assured drugs; and a 
recording and reporting system enabling 
outcome assessment. 
DOTS-Plus takes into account speciﬁ  c 
additional issues, such as the use of 
second-line drugs, that need to be 
addressed in areas where there is high 
prevalence of MDR-TB. DOTS-Plus works 
as a supplement to the standard DOTS 
strategy. By deﬁ  nition, it is impossible to 
conduct DOTS-Plus in an area without 
having an effective DOTS-based TB 
control program in place.
“We want to show other 
countries with similar 
problems what we 
learned.” 
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Training Centre to Disseminate 
Lessons Learned 
The state agency also includes a 
training centre. It offers research 
and training courses to TB experts 
from eastern Europe and central 
Asia. Since 2000, the training centre 
has held countless courses for 
program managers, social workers, 
nurses, and laboratory staff across 
Europe. Training modules focus on 
key issues such as improvement of 
laboratory diagnostic methods, 
patient education, and MDR-TB in 
prisons. So far 156 specialists have 
been trained.
In November 2004, the training 
centre was ofﬁ  cially awarded the status 
of a WHO Collaborating Centre, the 
ﬁ  rst one on MDR-TB in the European 
region. “We accumulated a lot of 
experience in the past years while 
implementing DOTS and DOTS-Plus”, 
says Dr. Vaira Leimane, director of the 
training centre. “We received a lot of 
help from donors. Now it is time for 
us to give back. We want to show other 
countries with similar problems what 
we learned, so that they can improve 
their capacity to effectively treat and 
control the disease.”
Co-Infection with TB and HIV
However, the battle is not won yet. A 
new public-health challenge is posed by 
the increasing number of patients with 
HIV/TB co-infection. Eastern Europe 
and central Asia are home to some of 
the fastest-growing epidemics, mostly 
among young people. People who are 
HIV-positive are more likely to become 
sick with TB and MDR-TB than others. 
In Latvia, according to the State Centre 
of TB and Lung Diseases, the number 
of patients co-infected with HIV and TB 
has risen from one in 1994 to 40 in 2003. 
Worldwide, in 2000, 11% of all 
new cases of TB in adults occurred in 
people infected with HIV, and 9% of 
the cases were directly attributable to 
HIV. The contribution of TB to AIDS-
related deaths is substantial: 11% of 
AIDS-related deaths occur primarily 
from TB [5]. 
Dr. Jack C. Chow, the WHO’s 
Assistant Director-General for HIV/
AIDS, TB, and Malaria, stresses that 
TB and HIV control programs must 
collaborate: “There are many ways how 
TB and HIV programs can closely work 
together. HIV-positive people can be 
given prophylactic treatment to prevent 
development of active TB disease. TB 
patients can be offered an HIV test.”
Without prompt action in this 
direction, years of Latvia’s successful 
TB control efforts could be 
undermined.  
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